Therefore, targeting RAGE, HMGB1, and S100A8/A9 will not only reduce immune suppression and facilitate antitumor immunity but may also delay tumor progression by neutralizing the many other mechanisms by which these molecules promote tumor growth. The gene discussed is HMGB1; the disease is neoplasm.